We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-4.53%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$539M
AUM Growth
+$38.3M
Cap. Flow
+$82.7M
Cap. Flow %
15.36%
Top 10 Hldgs %
44.1%
Holding
265
New
51
Increased
68
Reduced
40
Closed
62

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$17M
2
SWTX
SpringWorks Therapeutics
SWTX
+$9.56M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$8.73M
4
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$8.5M
5
SEPN
Septerna Inc
SEPN
+$8.23M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$10M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$6.65M
4
EDR
Endeavor Group Holdings, Inc.
EDR
+$6.59M
5
SNY icon
Sanofi
SNY
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 78.09%
2 Financials 3.23%
3 Technology 0.19%
4 Consumer Discretionary 0.05%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
201
CALL
DELISTED
Akero Therapeutics
AKRO
– –
-22,500
Closed -$626K
ALKS icon
202
Alkermes
ALKS
$8.25B
– –
-10,188
Closed -$293K
ALLK
203
DELISTED
Allakos
ALLK
– –
-62,264
Closed -$75.3K
ALNY icon
204
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-2,900
Closed -$682K
ALVO icon
205
Alvotech
ALVO
$1.29B
– –
-20,600
Closed -$273K
AMLX icon
206
CALL
Amylyx Pharmaceuticals
AMLX
$2.54B
– –
-10,000
Closed -$37.8K
AMPY icon
207
Amplify Energy
AMPY
$166M
– –
-18,475
Closed -$111K
ANAB icon
208
AnaptysBio
ANAB
$1.68B
– –
-27,301
Closed -$361K
APLT
209
CALL
DELISTED
Applied Therapeutics
APLT
– –
-530,324
Closed -$454K
ATAI icon
210
AtaiBeckley Inc
ATAI
$2.68B
– –
-100,000
Closed -$133K
AVIR icon
211
Atea Pharmaceuticals
AVIR
$420M
– –
-110,000
Closed -$369K
AXSM icon
212
Axsome Therapeutics
AXSM
$10.9B
– –
-19,661
Closed -$1.66M
BEAM icon
213
Beam Therapeutics
BEAM
$2.84B
– –
-38,312
Closed -$950K
BMRN icon
214
CALL
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-5,000
Closed -$329K
CAPR icon
215
CALL
Capricor Therapeutics
CAPR
$237M
– –
-95,000
Closed -$1.31M
CAPR icon
216
Capricor Therapeutics
CAPR
$237M
– –
-56,120
Closed -$774K
CDT icon
217
CDT Equity Inc
CDT
$2.16M
– –
0
– -$768
CRVS icon
218
CALL
Corvus Pharmaceuticals
CRVS
$1.17B
– –
-10,000
Closed -$53.5K
CRVS icon
219
PUT
Corvus Pharmaceuticals
CRVS
$1.17B
– –
-15,000
Closed -$80.3K
CYTK icon
220
CALL
Cytokinetics
CYTK
$10.4B
– –
-15,100
Closed -$710K
DHR icon
221
Danaher
DHR
$144B
– –
-4,000
Closed -$918K
DNA icon
222
Ginkgo Bioworks
DNA
$521M
– –
-18,680
Closed -$183K
CBIO
223
Crescent Biopharma
CBIO
$626M
– –
-3,318
Closed -$82.6K
GOSS icon
224
CALL
Gossamer Bio
GOSS
$87M
– –
-19,898
Closed -$18K
IBIO icon
225
iBio
IBIO
$70M
– –
-415,606
Closed -$1.02M
7 8
9
10 11

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, ADAR1 Capital Management held 265 positions worth $539M, up 7.7% from $500M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

ADAR1 Capital Management deployed $82.7M of net new capital in Q1 2025, opening 51 new positions and adding to 68 existing holdings. Its largest new stake was SpringWorks Therapeutics: 207,778 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $11.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2025 buy was SpringWorks Therapeutics: 207,778 shares worth $9.17M.
  • ADAR1 Capital Management added most to Keros Therapeutics in Q1 2025, an estimated $17M increase.
  • ADAR1 Capital Management's biggest Q1 2025 reduction was BridgeBio Pharma, cutting an estimated $11.4M.
  • ADAR1 Capital Management fully exited Endeavor Group Holdings, Inc. in Q1 2025, selling an estimated $6.59M.
  • ADAR1 Capital Management's ten largest holdings make up 44% of its $539M portfolio in Q1 2025.
  • ADAR1 Capital Management opened 51 new positions and closed 62 in Q1 2025.
  • ADAR1 Capital Management's portfolio value rose 7.7% quarter-over-quarter to $539M.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.